KRESTIN Fine Granules（云芝细粒）

简介：英文药名：KRESTIN Fine Granules 中文药名：云芝细粒 生产厂家：第一三共有限公司类别名称抗肿瘤药欧文商標名KRESTIN性状该药物是在细粒褐色或棕褐色，有轻微异味，没有味道。

关键字：云芝细粒 KRESTIN Fine Granules 抗肿瘤药 用于胃癌、大肠癌、小细胞肺癌.

英文药名：KRESTIN Fine Granules

中文药名：云芝细粒

生产厂家：第一三共有限公司
类别名称
抗肿瘤药
欧文商標名
KRESTIN
性状
该药物是在细粒褐色或棕褐色，有轻微异味，没有味道。它易溶于水，并在乙醇（95）几乎不溶。
溶解的状态
通过加入水100毫升溶解在药1克时，液体具有轻微混浊褐色。
药效药理
抗肿瘤作用
P388白血病中的系统在体外，人肝细胞株（C-CH-20）或其他合同显示抑制细胞生长的，在体内，肉瘤，一种系统大鼠肝癌的AH-13另一个相同种类的肿瘤等的，MC诱导的肉瘤（MC-2，MCS-8），Lewis肺癌，B-16，X5563等显示了对同基因肿瘤的抗肿瘤作用这是。
作用机序
增强体内由一个鼠同系肿瘤细胞（EL4）诱导的细胞毒活性。它增强针对在体外小鼠脾细胞（P815）的同种异体肿瘤细胞的细胞毒活性。
荷，并防止在产生抗体和迟发型脚掌反应的异源红细胞由（刘易斯，如肺癌）的能力的降低。
它抑制，可提高肿瘤的轴承（EL4）抑制器细胞的活性。
正常，增强荷瘤（MH134）和病毒感染的小鼠的NK细胞活性。
恢复了巨噬细胞趋化到由荷瘤（如EL4）降低。它增强了抗肿瘤细胞（SMT-2）的正常鼠腹腔巨噬细胞的生长抑制活性。
但回收的干扰素产生能力降低了肿瘤的轴承（MM102）。正常和肿瘤轴承（Car.755）增强了小鼠的IL-1，IL-2产生的能力。
引起的萎缩胸腺荷瘤（甲基甲），防止了在细胞中的数量减少。
的降低在由荷瘤从个体的免疫抑制物质，防止产生抗体和迟发型足垫反应的能力。
表明活化肠道免疫系统，如淋巴集结通过口服施用。
适合病症：
胃癌（手术病例），延长生存期通过联合化疗的患者和大肠癌（根治性手术）的病人。延长反应时间的化疗的组合等为小细胞肺癌  
剂量和给药方法
每日服用三次，每次1克
包装规格
クレスチン細粒
1g×84包

生产厂商
株式会社吴羽[联盟]第一三共有限公司

Therapeutic category name
Antineoplastic agents
Brand Name
Krestin fine
composition
And containing the following components in one capsule (1g)
Polysaccharide conjugated to protein, 1g those obtained from mycelium of Coriolus versicolor
Efficacy or effect
Gastric cancer (surgical case) prolonged survival by combination with chemotherapy in patients and colorectal cancer (curative resection) patients
Extension of the response period by the combination of chemotherapy and the like for small cell lung cancer
A day 3g I minute clothes 1-3 times.
Pharmacology
Antitumor action
P388 leukemia 10 in a system of in vitro), human liver cell line (C-CH-20) 11) or other contract shows the cytostatic, in a system of in vivo, Sarcoma180, rat hepatoma AH-1312) like the same kind of tumor other, MC-induced sarcoma (MC-213), MCS-814)), it showed the Lewis lung carcinoma, B-16, the anti-tumor effect against syngeneic tumor of the X5563, etc. 15).
Mechanism of action
16 enhanced the cytotoxic activity induced by a murine syngeneic tumor cells (EL4) in in vivo). 17 with enhanced cytotoxic activity against allogeneic tumor cells of mouse spleen cells (P815) in in vitro).
Tumor-bearing 18 to prevent a decrease in the ability to produce antibodies and delayed-type footpad reaction to the heterologous red blood cells by (Lewis, such as lung cancer)).
18 inhibited the suppressor cell activity that enhances the tumor-bearing (EL4)).
Normal 19), it enhanced the NK cell activity of tumor-bearing (MH134) 20) and virus infected mice 19).
21 to recover the macrophage chemotaxis to be lowered by tumor-bearing (such as EL4)). Normal rat peritoneal macrophages of tumor cells 22 enhanced the growth inhibitory activity against (SMT-2)).
23 recovered interferon production ability was reduced by tumor-bearing (MM102)). Normal and tumor-bearing (Car.755) IL-1, 24 which enhanced the IL-2-producing ability of the mouse).
Tumor-bearing (Meth A) of the thymus caused by atrophy, to prevent a reduction in the number of cells 25).
26 to prevent reduction in antibody production ability, and delayed-type footpad reaction according to tumor bearing individuals derived immunosuppressive agent).
27 shows the activation of the intestinal immune system, such as Peyer's patch by oral administration).
The physicochemical knowledge of active ingredient
Behavior
The drug is in the fine-grained a brownish or brown, there is a slightly peculiar smell, no taste. It is freely soluble in water, and practically insoluble in ethanol (95).
Dissolved state
When dissolved in the drug 1g by adding water 100mL, liquid has slight turbidity brown